Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05229601 · ClinicalTrials.gov registry record · Phase 1
A Study of HFB301001 in Adult Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by HiFiBiO Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05229601 is a Phase 1 study that was terminated before completion, run by HiFiBiO Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT05229601, a Phase 1 study, was terminated before completion, sponsored by HiFiBiO Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer they have.
Interventions
- DRUG HFB301001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-04-20 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05229601
The ClinicalTrials.gov registry entry for NCT05229601 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HiFiBiO Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HFB301001 is the first listed.
NCT05229601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05229601 about?
NCT05229601 is a clinical study titled "A Study of HFB301001 in Adult Patients With Advanced Solid Tumors". The purpose of this study is to test the safety and tolerability of HFB301001 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable doses of HFB301001 is determined. During the...
What is the current status of trial NCT05229601?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2022-04-20. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT05229601?
The interventions under investigation include: HFB301001 (DRUG).
Who is sponsoring clinical trial NCT05229601?
This trial is sponsored by HiFiBiO Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.